Janssen Research & Development announced that it has filed a New Drug Application to the U.S. Food and Drug Administration for a once-daily fixed-dose antiretroviral combination tablet containing its protease inhibitor Prezista with Gilead Sciences' cobicistat, an investigational pharmacokinetic enhancer for use in combination with other human ... (more)
http://ift.tt/1ovmDLw
http://ift.tt/1ovmDLw
No comments:
Post a Comment